> Detailanzeige

Di Filippo, Yoann; Dalle, Stéphane; Mortier, Laurent; Dutriaux, Caroline; Dalac, Sophie; Leccia, Marie Thérèse; Legoupil, Delphine; Saiag, Philippe; Brunet-Possenti, Florence; Arnault, Jean-Philippe; Maubec, Eve; Granel-Brocard, Florence; De Quatrebarbes, Julie; Aubin, Francois; Lesimple, Thierry; Stoebner, Pierre-Emmanuel; Lefevre, Wendy; Dereure, Olivier; Lebbe, Celeste; Montaudie, Henri

Does body mass index really predict the response to systemic therapies in metastatic melanoma: A multicenter study from the MelBase French National Cohort?

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: Does body mass index really predict the response to systemic therapies in metastatic melanoma: A multicenter study from the MelBase French National Cohort?
  • Beteiligte: Di Filippo, Yoann; Dalle, Stéphane; Mortier, Laurent; Dutriaux, Caroline; Dalac, Sophie; Leccia, Marie Thérèse; Legoupil, Delphine; Saiag, Philippe; Brunet-Possenti, Florence; Arnault, Jean-Philippe; Maubec, Eve; Granel-Brocard, Florence; De Quatrebarbes, Julie; Aubin, Francois; Lesimple, Thierry; Stoebner, Pierre-Emmanuel; Lefevre, Wendy; Dereure, Olivier; Lebbe, Celeste; Montaudie, Henri
  • Erschienen: American Society of Clinical Oncology (ASCO), 2020
  • Erschienen in: Journal of Clinical Oncology, 38 (2020) 15_suppl, Seite 10031-10031
  • Sprache: Englisch
  • DOI: 10.1200/jco.2020.38.15_suppl.10031
  • ISSN: 1527-7755; 0732-183X
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: 10031 Background: Obesity is an established risk factor for several cancers and higher body mass index (BMI) is associated with poor prognosis. These data are still debated in melanoma. Furthermore, recently the concept of “obesity paradox” has emerged. In a large cohort published by McQuade JL et al, higher BMI was associated with better survival in patients with metastatic melanoma (MM) especially for those treated with targeted therapy (TT) and immune checkpoint inhibitors (ICI). We studied the association between BMI and progression-free survival (PFS) and overall survival (OS) in patients with MM treated with systemic therapies. Methods: This study was conducted from the prospective MelBase cohort (NCT02828202). Patients with MM treated with first-line ICI, TT, or CT were included. BMI was categorized by WHO criteria. Underweight patients were excluded. The co-primary outcomes were the associations between BMI and PFS or OS, stratified by treatment, sex and age. Multivariate analyses were performed. Results: A total of 1214 patients were analyzed. The majority of them were treated with ICI, followed by TT. Obese patients represented 22% of cohort (Table). Median follow-up was 13.5 months. The patients who were overweight or obese did not have different PFS (p = 0.88) or OS (p = 0.25) than patients with normal BMI. Stratifying this cohort by treatment received, age, sex and others parameters (such as LDH, number of metastatic site) did not revealed any difference. Multivariate analysis did not change the results. Conclusions: BMI was not associated with clinical outcomes in our cohort, especially in ICI and TT groups. Thus, we did not confirm the results presented by McQuade Jl et al. with a cohort quite similar in term of size. Because BMI is too simplistic and then an imperfect measure of body composition, the published data are not reproducible. We caution the oncologists, about BMI as valuable predictive marker of survival for melanoma patients. [Table: see text]
  • Zugangsstatus: Freier Zugang